Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Rosetta signs microRNA gene licensing agreement with Rockefeller University

Rosetta Genomics : 30 April, 2008  (Company News)
Rosetta Genomics has signed a non-exclusive licensing agreement with Rockefeller University for research application of proprietary microRNA genes.
The agreement encompasses viral and human microRNAs that will be added to Rosetta Genomics' existing intellectual property (IP) estate, which includes two issued patents, two allowed patent applications, and 60 pending patent applications.

'As leaders in the microRNA field, we view our strong intellectual property position as a key component of our business strategy, allowing us the freedom to advance the company and its pipeline.' said Amir Avniel, president and chief executive officer of Rosetta. 'Our strategy continues to focus on supplementing our in-house IP portfolio with licensing agreements with key academic centres such as Rockefeller University.'

Rosetta Genomics has previously licensed Rockefeller University's proprietary microRNAs for therapeutic and diagnostic uses, and this recent agreement allows the company access to a full range of potential microRNA applications based on these microRNAs.


In addition to its non-exclusive license of Rockefeller University's microRNAs, Rosetta Genomics estimates it has exclusive access to the majority of known microRNA genes through proprietary microRNAs discovered at Rosetta Genomics and microRNAs co-discovered by The Johns Hopkins University School of Medicine and exclusively licensed to the company. In addition, the company has non-exclusively licensed for research and diagnostic applications microRNAs discovered by the Max Planck Society. From this IP position, Rosetta Genomics is developing a wide range of microRNA-based diagnostic tests for cancer and other indications.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo